<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423434</url>
  </required_header>
  <id_info>
    <org_study_id>DP3DK104386</org_study_id>
    <secondary_id>1DP3DK104386-01</secondary_id>
    <nct_id>NCT02423434</nct_id>
  </id_info>
  <brief_title>Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes</brief_title>
  <official_title>Multinational Collaborative Evaluation of Corneal Confocal Microscopy as a Surrogate Endpoint for the Identification and Prediction of Diabetic Neuropathy in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queensland University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through the multinational pooled dataset approach, this trial will aim to derive and validate
      specific in vivo Corneal Confocal Microscopy (CCM) parameter thresholds for the
      identification of diabetic polyneuropathy, and - more importantly - the identification of
      individuals at future risk. Results of the study will permit application in clinical practice
      and intervention trials for diabetic polyneuropathy (DPN) risk stratification.

      The primary goal of the study is to re-examine individuals with type 1 and type 2 diabetes
      with and without neuropathy, who had CCM performed in the past as a part of their
      neurological examination, to assess concurrent and predictive validity of different CCM
      parameters in individuals . These subjects will be invited to the study to be re-examined by
      CCM along with other neurological tests (physical exam, nerve conduction studies,
      quantitative sensory testing, blood test and in some centres also skin biopsy) during the
      single study visit. Additionally CCM data will be analyzed both manually and by recently
      developed automated analytical software to evaluate accuracy of the automated method.
      Evaluation of automated image analysis will influence likelihood of successful knowledge
      translation of this surrogate biomarker for DPN into clinical practice - in which the
      procedure could be harmonized with annual retinal examinations - and into intervention
      trials.

      Secondary aim of the study is to determine the factors associated with CCM parameters and
      their longitudinal change and collect bio-samples for future research in this field.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diffuse injury to peripheral nerves (diabetic neuropathy) is exceptionally common in type
      1 diabetes, but there is a lack of an objective surrogate marker to identify early
      subclinical stages when treatments might be most effective, prior to late-stage progression
      to troublesome and costly foot infection, ulceration, and limb amputation. In contrast to the
      ability to objectively measure disease-specific surrogate markers for retinopathy and
      nephropathy, this lack of a diabetic neuropathy surrogate marker has seriously impeded the
      development of specific interventions in clinical research trials. Representing 5 independent
      research groups that have together created a consortium of investigators dedicated to the
      development of a surrogate marker for early diabetic neuropathy, we have focused on using the
      eye as a window to non-invasively image by a method of in-vivo corneal confocal microscopy
      (CCM) the small nerve fibres that innervate the cornea. We have demonstrated that changes in
      these nerve fibre endings occur early in the development of neuropathy, reflect well the
      changes seen in other peripheral nerves by invasive skin biopsy evaluation, and that their
      measurement is feasible and reproducible. As a multinational consortium, we have the benefit
      in this proposal of pooling multiple cohorts to apply the most valid study methods in
      biomarker development. First, we aim to determine in the analysis of an existing pooled
      dataset of 516 type 1 and 524 type 2 diabetes subjects the exact levels of CCM measurement
      that can identify the presence of diabetic neuropathy. Secondly, we propose over three years
      to re-examine at least 70% of this cohort, which will provide 5- to 7-year follow-up data to
      determine which type and level of CCM measurement can predict the future onset of neuropathy,
      as well as its progression in those who had neuropathy at baseline. Finally, we will evaluate
      the role of time- and cost-saving automated image analysis software. By virtue of large
      sample size from data pooling, we are uniquely afforded the methodological power to confirm
      our objectives by way of separate derivation and validation analysis sets. Through a unique
      and unprecedented multinational pooled dataset approach for diabetic neuropathy, this work
      will derive and validate specific CCM parameter thresholds for the identification of
      neuropathy, and - more importantly - the identification of individuals at future risk. These
      results will permit application in clinical practice and intervention trials for neuropathy
      risk stratification. Evaluation of automated image analysis will influence likelihood of
      successful knowledge translation of this surrogate biomarker into clinical practice - in
      which the procedure could be harmonized with annual retinal examinations - and into
      intervention trials.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Concurrent Validity of CCM Parameters from Cross-Sectional Analysis of Well-Characterized T1D and T2D Subjects.</measure>
    <time_frame>Any data obtained from pre-study measurements</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the Predictive Validity of CCM Parameters based on the 5-7 year Incidence of Neuropathy in Well-Characterized T1D and T2D Subjects Without Neuropathy at Baseline</measure>
    <time_frame>Study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the Predictive Validity of CCM Parameters for 5-7 year Progression of Neuropathy</measure>
    <time_frame>Study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Manual versus Automated Image analysis</measure>
    <time_frame>Pre-study and study visit data</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the Factors associated with CCM Parameters and their Longitudinal Change</measure>
    <time_frame>Study visit</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">729</enrollment>
  <condition>Diabetic Polyneuropathy</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Corneal Confocal Microscopy subjects</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure: Corneal nerve fibre morphology by the CCM Procedure</intervention_name>
    <description>CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.
In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed.</description>
    <arm_group_label>Corneal Confocal Microscopy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This longitudinal observational cohort study of diagnosis involves follow-up in two study
        groups:

        A. Five- to seven-year follow-up re-examination of 5 well-characterized type 1 diabetes
        (T1D) cohorts (N=516) comprising a neuropathic subset and a non-neuropathic subset.

        B. Three- to six-year follow-up re-examination of 4 well-characterized type 2 diabetes
        (T2D) cohorts (N=524) each comprising a neuropathic subset and a non-neuropathic subset.

        T1D Subjects. The five study sites are composed of cohort studies for T1D initiated between
        2008 and 2011. Together, the five sites have studied 516 subjects at baseline with T1D, 363
        without DPN and 151 with DPN at baseline.

        T2D Subjects. Four of the sites have studied subjects with T2D. Together, the four sites
        have studied 524 subjects at baseline with T2D, 241 without DPN and 283 with DPN at
        baseline.

        Of the 1040 total subjects examined in baseline procedures, we anticipate follow-up of 70%
        for a total re-examined cohort 729.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of any gender or race aged 18 or above

          -  Type 1 diabetes mellitus or type 2 diabetes mellitus as defined by the American
             Diabetes Association guidelines (2014) of any duration

          -  Availability of the initial CCM examination performed two to eight years ago

          -  Ability to understand and cooperate with study procedures

        Exclusion Criteria:

          -  Confirmed to have neuropathy owing to non-diabetic causes (such as familial,
             alcoholic, nutritional, uremic)

          -  Current eye infection, corneal damage, or severe movement disorders which could
             preclude a safe CCM exam

          -  Allergy to proparacaine (the ocular topical anaesthetic used for the CCM exam)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce A Perkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queensland University of Technology</name>
      <address>
        <city>Brisbane</city>
        <zip>4059</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital and University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M139PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tavakoli M, Ferdousi M, Petropoulos IN, Morris J, Pritchard N, Zhivov A, Ziegler D, Pacaud D, Romanchuk K, Perkins BA, Lovblom LE, Bril V, Singleton JR, Smith G, Boulton AJ, Efron N, Malik RA. Normative values for corneal nerve morphology assessed using corneal confocal microscopy: a multinational normative data set. Diabetes Care. 2015 May;38(5):838-43. doi: 10.2337/dc14-2311. Epub 2015 Jan 29.</citation>
    <PMID>25633665</PMID>
  </reference>
  <reference>
    <citation>Pritchard N, Edwards K, Russell AW, Perkins BA, Malik RA, Efron N. Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes. Diabetes Care. 2015 Apr;38(4):671-5. doi: 10.2337/dc14-2114. Epub 2015 Jan 8.</citation>
    <PMID>25573881</PMID>
  </reference>
  <reference>
    <citation>Tavakoli M, Begum P, McLaughlin J, Malik RA. Corneal confocal microscopy for the diagnosis of diabetic autonomic neuropathy. Muscle Nerve. 2015 Sep;52(3):363-70. doi: 10.1002/mus.24553. Epub 2015 Jun 18.</citation>
    <PMID>25556884</PMID>
  </reference>
  <reference>
    <citation>Dehghani C, Pritchard N, Edwards K, Vagenas D, Russell AW, Malik RA, Efron N. Natural history of corneal nerve morphology in mild neuropathy associated with type 1 diabetes: development of a potential measure of diabetic peripheral neuropathy. Invest Ophthalmol Vis Sci. 2014 Nov 18;55(12):7982-90. doi: 10.1167/iovs.14-15605.</citation>
    <PMID>25406279</PMID>
  </reference>
  <reference>
    <citation>Maddaloni E, Sabatino F, Del Toro R, Crugliano S, Grande S, Lauria Pantano A, Maurizi AR, Palermo A, Bonini S, Pozzilli P, Manfrini S. In vivo corneal confocal microscopy as a novel non-invasive tool to investigate cardiac autonomic neuropathy in Type 1 diabetes. Diabet Med. 2015 Feb;32(2):262-6. doi: 10.1111/dme.12583. Epub 2014 Sep 24.</citation>
    <PMID>25251450</PMID>
  </reference>
  <reference>
    <citation>Stem MS, Hussain M, Lentz SI, Raval N, Gardner TW, Pop-Busui R, Shtein RM. Differential reduction in corneal nerve fiber length in patients with type 1 or type 2 diabetes mellitus. J Diabetes Complications. 2014 Sep-Oct;28(5):658-61. doi: 10.1016/j.jdiacomp.2014.06.007. Epub 2014 Jun 17.</citation>
    <PMID>25044236</PMID>
  </reference>
  <reference>
    <citation>Asghar O, Petropoulos IN, Alam U, Jones W, Jeziorska M, Marshall A, Ponirakis G, Fadavi H, Boulton AJ, Tavakoli M, Malik RA. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care. 2014 Sep;37(9):2643-6. doi: 10.2337/dc14-0279. Epub 2014 Jun 26.</citation>
    <PMID>24969581</PMID>
  </reference>
  <reference>
    <citation>Edwards K, Pritchard N, Vagenas D, Russell A, Malik RA, Efron N. Standardizing corneal nerve fibre length for nerve tortuosity increases its association with measures of diabetic neuropathy. Diabet Med. 2014 Oct;31(10):1205-9. doi: 10.1111/dme.12466. Epub 2014 May 24.</citation>
    <PMID>24750318</PMID>
  </reference>
  <reference>
    <citation>Ziegler D, Papanas N, Zhivov A, Allgeier S, Winter K, Ziegler I, Brüggemann J, Strom A, Peschel S, Köhler B, Stachs O, Guthoff RF, Roden M; German Diabetes Study (GDS) Group. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014 Jul;63(7):2454-63. doi: 10.2337/db13-1819. Epub 2014 Feb 26.</citation>
    <PMID>24574045</PMID>
  </reference>
  <reference>
    <citation>Petropoulos IN, Alam U, Fadavi H, Marshall A, Asghar O, Dabbah MA, Chen X, Graham J, Ponirakis G, Boulton AJ, Tavakoli M, Malik RA. Rapid automated diagnosis of diabetic peripheral neuropathy with in vivo corneal confocal microscopy. Invest Ophthalmol Vis Sci. 2014 Apr 3;55(4):2071-8. doi: 10.1167/iovs.13-13787.</citation>
    <PMID>24569580</PMID>
  </reference>
  <reference>
    <citation>Tavakoli M, Petropoulos IN, Malik RA. Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot. J Diabetes Sci Technol. 2013 Sep 1;7(5):1179-89. Review.</citation>
    <PMID>24124944</PMID>
  </reference>
  <reference>
    <citation>Petropoulos IN, Alam U, Fadavi H, Asghar O, Green P, Ponirakis G, Marshall A, Boulton AJ, Tavakoli M, Malik RA. Corneal nerve loss detected with corneal confocal microscopy is symmetrical and related to the severity of diabetic polyneuropathy. Diabetes Care. 2013 Nov;36(11):3646-51. doi: 10.2337/dc13-0193. Epub 2013 Jul 22.</citation>
    <PMID>23877983</PMID>
  </reference>
  <reference>
    <citation>Papanas N, Ziegler D. Corneal confocal microscopy: a new technique for early detection of diabetic neuropathy. Curr Diab Rep. 2013 Aug;13(4):488-99. doi: 10.1007/s11892-013-0390-z. Review.</citation>
    <PMID>23666893</PMID>
  </reference>
  <reference>
    <citation>Sivaskandarajah GA, Halpern EM, Lovblom LE, Weisman A, Orlov S, Bril V, Perkins BA. Structure-function relationship between corneal nerves and conventional small-fiber tests in type 1 diabetes. Diabetes Care. 2013 Sep;36(9):2748-55. doi: 10.2337/dc12-2075. Epub 2013 Apr 11.</citation>
    <PMID>23579181</PMID>
  </reference>
  <reference>
    <citation>Halpern EM, Lovblom LE, Orlov S, Ahmed A, Bril V, Perkins BA. The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. J Diabetes Complications. 2013 May-Jun;27(3):240-2. doi: 10.1016/j.jdiacomp.2012.10.011. Epub 2012 Dec 21.</citation>
    <PMID>23266297</PMID>
  </reference>
  <reference>
    <citation>Shtein RM, Callaghan BC. Corneal confocal microscopy as a measure of diabetic neuropathy. Diabetes. 2013 Jan;62(1):25-6. doi: 10.2337/db12-1114.</citation>
    <PMID>23258907</PMID>
  </reference>
  <reference>
    <citation>Efron N. Assessing diabetic neuropathy using corneal confocal microscopy. Invest Ophthalmol Vis Sci. 2012 Dec 7;53(13):8075. doi: 10.1167/iovs.12-11308.</citation>
    <PMID>23221463</PMID>
  </reference>
  <reference>
    <citation>Tavakoli M, Petropoulos IN, Malik RA. Assessing corneal nerve structure and function in diabetic neuropathy. Clin Exp Optom. 2012 May;95(3):338-47. doi: 10.1111/j.1444-0938.2012.00743.x. Review.</citation>
    <PMID>22594548</PMID>
  </reference>
  <reference>
    <citation>Wu T, Ahmed A, Bril V, Orszag A, Ng E, Nwe P, Perkins BA. Variables associated with corneal confocal microscopy parameters in healthy volunteers: implications for diabetic neuropathy screening. Diabet Med. 2012 Sep;29(9):e297-303. doi: 10.1111/j.1464-5491.2012.03678.x.</citation>
    <PMID>22519850</PMID>
  </reference>
  <reference>
    <citation>Ahmed A, Bril V, Orszag A, Paulson J, Yeung E, Ngo M, Orlov S, Perkins BA. Detection of diabetic sensorimotor polyneuropathy by corneal confocal microscopy in type 1 diabetes: a concurrent validity study. Diabetes Care. 2012 Apr;35(4):821-8. doi: 10.2337/dc11-1396. Epub 2012 Feb 8.</citation>
    <PMID>22323412</PMID>
  </reference>
  <reference>
    <citation>Dabbah MA, Graham J, Petropoulos IN, Tavakoli M, Malik RA. Automatic analysis of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging. Med Image Anal. 2011 Oct;15(5):738-47. doi: 10.1016/j.media.2011.05.016. Epub 2011 Jun 13.</citation>
    <PMID>21719344</PMID>
  </reference>
  <reference>
    <citation>Tavakoli M, Kallinikos P, Iqbal A, Herbert A, Fadavi H, Efron N, Boulton AJ, A Malik R. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med. 2011 Oct;28(10):1261-7. doi: 10.1111/j.1464-5491.2011.03372.x.</citation>
    <PMID>21699561</PMID>
  </reference>
  <reference>
    <citation>Malik RA, Veves A, Tesfaye S, Smith G, Cameron N, Zochodne D, Lauria G; Toronto Consensus Panel on Diabetic Neuropathy. Small fibre neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab Res Rev. 2011 Oct;27(7):678-84. doi: 10.1002/dmrr.1222.</citation>
    <PMID>21695760</PMID>
  </reference>
  <reference>
    <citation>Hertz P, Bril V, Orszag A, Ahmed A, Ng E, Nwe P, Ngo M, Perkins BA. Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. Diabet Med. 2011 Oct;28(10):1253-60. doi: 10.1111/j.1464-5491.2011.03299.x.</citation>
    <PMID>21434993</PMID>
  </reference>
  <reference>
    <citation>Pritchard N, Edwards K, Shahidi AM, Sampson GP, Russell AW, Malik RA, Efron N. Corneal markers of diabetic neuropathy. Ocul Surf. 2011 Jan;9(1):17-28. Review.</citation>
    <PMID>21338566</PMID>
  </reference>
  <reference>
    <citation>Efron N, Edwards K, Roper N, Pritchard N, Sampson GP, Shahidi AM, Vagenas D, Russell A, Graham J, Dabbah MA, Malik RA. Repeatability of measuring corneal subbasal nerve fiber length in individuals with type 2 diabetes. Eye Contact Lens. 2010 Sep;36(5):245-8. doi: 10.1097/ICL.0b013e3181eea915.</citation>
    <PMID>20724854</PMID>
  </reference>
  <reference>
    <citation>Messmer EM, Schmid-Tannwald C, Zapp D, Kampik A. In vivo confocal microscopy of corneal small fiber damage in diabetes mellitus. Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1307-12. doi: 10.1007/s00417-010-1396-8. Epub 2010 May 21.</citation>
    <PMID>20490534</PMID>
  </reference>
  <reference>
    <citation>Tavakoli M, Quattrini C, Abbott C, Kallinikos P, Marshall A, Finnigan J, Morgan P, Efron N, Boulton AJ, Malik RA. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care. 2010 Aug;33(8):1792-7. doi: 10.2337/dc10-0253. Epub 2010 Apr 30.</citation>
    <PMID>20435796</PMID>
  </reference>
  <reference>
    <citation>Midena E, Brugin E, Ghirlando A, Sommavilla M, Avogaro A. Corneal diabetic neuropathy: a confocal microscopy study. J Refract Surg. 2006 Nov;22(9 Suppl):S1047-52.</citation>
    <PMID>17444092</PMID>
  </reference>
  <reference>
    <citation>Mocan MC, Durukan I, Irkec M, Orhan M. Morphologic alterations of both the stromal and subbasal nerves in the corneas of patients with diabetes. Cornea. 2006 Aug;25(7):769-73.</citation>
    <PMID>17068451</PMID>
  </reference>
  <reference>
    <citation>Hossain P, Sachdev A, Malik RA. Early detection of diabetic peripheral neuropathy with corneal confocal microscopy. Lancet. 2005 Oct 15-21;366(9494):1340-3.</citation>
    <PMID>16226599</PMID>
  </reference>
  <reference>
    <citation>Kallinikos P, Berhanu M, O'Donnell C, Boulton AJ, Efron N, Malik RA. Corneal nerve tortuosity in diabetic patients with neuropathy. Invest Ophthalmol Vis Sci. 2004 Feb;45(2):418-22.</citation>
    <PMID>14744880</PMID>
  </reference>
  <reference>
    <citation>Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, Boulton AJ. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003 May;46(5):683-8. Epub 2003 May 9.</citation>
    <PMID>12739016</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corneal Confocal Microscopy</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Diabetic Neuropathy</keyword>
  <keyword>Diabetes Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

